J&J last month recently reported favorable results from a Phase 2 study of TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer who are ineligible or refuse neoadjuvant ...
In response to the FDA request, there is a demonstrated duration of CR of 13.2% (9/68) at 540 days, 8.8% (6/68) at 630 days, 7.4% (5/68) at 720 days, 7.4% (5/68) at 900 days and 5.9% (4/68) at 1080 ...
“Incontinence and overactive bladder are among the biggest risk ... but their classes focused on nonspecific stretching and strengthening exercises that did not engage the pelvic floor.
Nighttime bathroom trips can wreak havoc on your sleep, but there are some practical ways to manage them. A doctor provides six tips to improve your rest.